کد مقاله کد نشریه سال انتشار مقاله انگلیسی نسخه تمام متن
2408522 1103177 2007 7 صفحه PDF دانلود رایگان
عنوان انگلیسی مقاله ISI
Protection against cutaneous leishmaniasis by intranasal vaccination with lipophosphoglycan
موضوعات مرتبط
علوم زیستی و بیوفناوری ایمنی شناسی و میکروب شناسی ایمونولوژی
پیش نمایش صفحه اول مقاله
Protection against cutaneous leishmaniasis by intranasal vaccination with lipophosphoglycan
چکیده انگلیسی

We previously showed the opposing effect of systemic and mucosal vaccination with whole Leishmania amazonensis antigen (LaAg). Here, the role played by lipophosphoglycan (LPG) as the key disease-promoting component of intramuscular (i.m.) LaAg and its usefulness as a defined intranasal vaccine was investigated in murine cutaneous leishmaniasis. BALB/c mice were twice vaccinated by the i.m. route with 25 μg of intact LaAg or with LaAg that was pretreated with anti-LPG 3A1-La monoclonal antibody, prior to infection with L. amazonensis. LPG neutralization rendered the otherwise disease-promoting LaAg antigen protective, as observed by the smaller lesion sizes and reduced parasite burden. The increased resistance was accompanied by a markedly lower antigen-driven TGF-β and IL-10 responses in the lesion-draining lymph nodes, concomitant with significantly higher IFN-γ production. To test for intranasal efficacy, 10 μg of affinity-purified LPG and its parental LaAg were twice instilled in the nostrils prior to L. amazonensis infection. In both cases, similarly slower lesion growth and lower parasite burden were found that was associated with increased IFN-γ and IL-10 responses in the lesion-draining lymph nodes. These results support a role for LPG in the dual route-related effect of LaAg and shows its strong potential as a defined needle-free and adjuvant-free vaccine for cutaneous leishmaniasis.

ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Vaccine - Volume 25, Issue 14, 30 March 2007, Pages 2716–2722
نویسندگان
, , , , , , , ,